Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Non-Hodgkin lymphoma Stories

2013-06-19 16:26:56

A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition RARITAN, N.J., June 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that a study published online in The New England Journal of Medicine (NEJM) demonstrates treatment with ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, resulted in an overall response rate of 68%, with 47% of patients achieving a partial...

2013-06-13 08:28:52

Company Earns $6 Million Milestone Payment from Eisai for Trial Initiation CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to assess the safety, tolerability and pharmacokinetics of EPZ-6438...

2013-05-22 16:25:27

Anti-CD20-Interferon Alpha Fusion Protein (IGN002) is a promising drug candidate for NHL patients who are resistant to standard therapy WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6( )million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change...

2013-04-24 12:26:19

Faster approvals needed for coverage by provincial drug plans: Lymphoma Foundation Canada TORONTO, April 24, 2013 /CNW/ - The recent approval by Health Canada of a highly effective new treatment for non-Hodgkin lymphoma and the subsequent decision by several provinces to cover the cost for cancer patients is very good news, says Lymphoma Foundation Canada (LFC).  However, the organization says more must be done to speed up the coverage by provincial drug plans for a host of...

2013-04-10 20:21:56

SEATTLE, April 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). The draft guidance does not...

2013-02-06 16:26:48

WHITE PLAINS, N.Y., Feb. 6, 2013 /PRNewswire/ -- Blood cancer patients with chronic, disabling, and life threatening conditions such as leukemia, non-Hodgkin's and Hodgkin's lymphoma and myeloma are in jeopardy of losing access to critical medications. Some health insurance companies are now placing biologic drugs and certain cancer medications into "specialty tiers" that require patients to pay 20 to 50 percent of drug costs, amounting to hundreds or even thousands of dollars in...

2012-10-17 07:26:19

ALBANY, New York, October 17, 2012 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database B- Cell Non- Hodgkin Lymphoma - Pipeline Review, H2 2012 [http://www.marketresearchreports.biz/analysis/138044 ] Global Markets Directs, 'B-Cell Non-Hodgkin Lymphoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Non-Hodgkin...

2012-10-15 11:27:35

WHITE PLAINS, N.Y., Oct. 15, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was saddened to learn of the death of Senator Arlen Specter from complications related to non-Hodgkin lymphoma. Specter, Senator from Pennsylvania from 1980 until 2010, had previously fought Hodgkin's disease in 2005, and later survived a brain tumor and heart bypass surgery. Specter was an ardent advocate for medical research, continually pushing for more funding for the National Institutes of...

2012-08-23 10:24:23

WHITE PLAINS, N.Y., Aug. 23, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish- and Portuguese-speaking patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) and their families. On Thursday, September 13 from 1:00 to 2:30 PM Eastern Time, Dr. Christopher R. Flowers from the Winship Cancer Institute of...

2012-08-22 12:19:10

A University of Rochester Medical Center study challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis. The research underlines the fact that when cancer strikes, modern patients and their oncologists across the United States are taking many diverse treatment paths when there is scant data to support one method over another. This study...